Abstract: The present disclosure relates to biomarkers for predicting clinical response of a VEGF-A (vascular endothelial growth factor A) inhibitory drug in cancer therapy. In particular, the disclosure provides a multi-gene expression signature score named ViRP (VEGF inhibitory Response Predictor) able to predict response to a VEGF-A inhibitory drug in a patient being diagnosed with a solid cancerous tumor.

Abstract: Methods for identifying and treating cancers that are DNA repair, such as homologous recombination (HR) repair, defective or sensitive to PARP inhibitors or platinum-based therapy. In some aspects, DNA repair, such as HR repair, defective cancers are treated with a PARP inhibitor therapy or cisplatin. Methods for sensitizing cancers to a PARP inhibitor therapy are also provided.

Abstract: Methods for identifying and treating cancers that are DNA repair, such as homologous recombination (HR) repair, defective or sensitive to PARP inhibitors or platinum-based therapy. In some aspects, DNA repair, such as HR repair, defective cancers are treated with a PARP inhibitor therapy or cisplatin. Methods for sensitizing cancers to a PARP inhibitor therapy are also provided.

Abstract: The present invention relates to, among other things, probes, compositions, methods, and kits for simultaneous, multiplexed detection and quantification of protein expression in a user-defined region of a tissue, user-defined cell, and/or user-defined subcellular structure within a cell.

Abstract: The present invention relates to, among other things, probes, compositions, methods, and kits for simultaneous, multiplexed detection and quantification of protein expression in a user-defined region of a tissue, user-defined cell, and/or user-defined subcellular structure within a cell.

Abstract: Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. Variable domain and complementarity determining region amino acid sequences of several monoclonal antibodies against LPA are disclosed, as is a consensus anti-LPA monoclonal antibody variable domain sequence.

Abstract: Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. Variable domain and complementarity determining region amino acid sequences of several monoclonal antibodies against LPA are disclosed, as is a consensus anti-LPA monoclonal antibody variable domain sequence.

Abstract: Genomic analysis of ovarian cancers demonstrated a regional chromosomal increase in expression and gene duplication. TGF-? stimulation indicated a link between SnoN RNA and TGF-?. In TIOSE, SnoN protein levels were reduced 15 min post TGF-?-stimulation, likely by proteosome-mediated degradation. SnoN inhibition decreased cell growth between 20 and 50% concurrent with increased p21 levels. Stable expression of SnoN led to growth arrest through induction of senescence. Collectively, these results implicate SnoN levels in multiple roles during ovarian carcinogenesis: promoting cellular proliferation in ovarian cancer cells and as a positive mediator of cell cycle arrest and senescence in non-transformed ovarian epithelial cells.

Abstract: Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. Variable domain and complementarity determining region amino acid sequences of several monoclonal antibodies against LPA are disclosed, as is a consensus anti-LPA monoclonal antibody variable domain sequence.

Abstract: The present invention involves compositions and methods for assessing protein interactions in eukaryotic cells. Certain embodiments involve Retrovirus-Based Molecular Two-Hybrid Screens (ReMTH). ReMTH screens differ from other methods by performing screens in the native cellular hosts without cDNA library construction. Embodiments of the invention use the advantages of tagging endogenous genes with an exon encoding a marker fragment in combination with protein-fragment complementation assays (PCAs), which includes the complementation of at least two marker fragments to form a detectable marker complex. ReMTH vectors insert a nucleotide sequence encoding a first fragment of a marker, such as green fluorescent protein (GFP), into an endogenous gene resulting in expression of random endogenous genes tagged with a first marker fragment forming an endogenous prey protein or prey protein. ReMTH contain cells also express a bait protein that is fused with a second marker fragment.

Abstract: The invention provides method for predicting whether a cancer patient will respond to a therapy. Methods of the invention may involve examining protein from a cell of the cancer patient by determining the binding of a panel of antibodies to the protein. Methods of the invention may be used to generate both expression and activation profiles for cells from a cancer patient. Profiles from a cancer patient may then be compared to known profiles for therapy responders and non-responders to predict the individual response of the patient. For example, methods of the invention may be used to determine whether an ovarian or breast cancer patient will respond to a therapeutic protocol.

Abstract: The present invention provides phosphoric acid and phosphoric acid compounds as well as thioderivatives thereof of formulat (I, II, III, IV and V).

Abstract: The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent.

Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers are provided.

Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers. A variety of markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of ovarian cancer.